Prevention of cytomegalovirus reactivaction after allogenic hematopoietic stem cell transplantation with valganciclovir: single center experience.
Rzepecki
P
P
BMT Unit, Department of Oncology, Military Institute of Health Services, Warsaw, Poland. piotr_rzepecki@poczta@poczta.onet.pl
Barzal
J
J
Sarosiek
T
T
Oborska
S
S
Szczylik
C
C
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control* / Q000821:virology; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D055502:Secondary Prevention; D014184:Transplantation, Homologous; D000077562:Valganciclovir
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir